Heparin-Induced Thrombocytopenia Platelet Aggregation Studies in the Presence of Heparin Fractions or Semi-Synthetic Analogues of Various Molecular Weights and Anticoagulant Activities

D Blockmans; H Bounameaux; J Vermylen; M Verstraete

doi:10.1055/s-0038-1661454

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1986; 55(01): 090-093
DOI: 10.1055/s-0038-1661454

Original Article

Schattauer GmbH Stuttgart

Heparin-Induced Thrombocytopenia Platelet Aggregation Studies in the Presence of Heparin Fractions or Semi-Synthetic Analogues of Various Molecular Weights and Anticoagulant Activities

D Blockmans

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium

,

H Bounameaux

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium

,

J Vermylen

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium

,

M Verstraete

The Center for Thrombosis and Vascular Research, University of Leuven, Belgium

› Author Affiliations

Abstract

PDF Download

Summary

One case of heparin-induced thrombocytopenia is reported. Aggregation was observed in the platelet-rich plasma of this patient in the presence of two commercial standard heparin preparations (from a final concentration of 0.025 IU/ml upwards), of two semi-synthetic heparin analogues (0.1 APTT U/ml) and of three low-molecular weight heparin (LMWH) fractions (0.1 anti-Xa U/ml) but not in the presence of five other LMWH fractions.

The patient’s isolated platelets no longer aggregated in the presence of heparin but the phenomenon recurred after addition of the patient’s platelet poor plasma (PPP).

Furthermore, addition of patient’s PPP to control platelets led to heparin-induced aggregation.

The phenomenon was associated with thromboxane generation and could be blocked by in vitro addition of aspirin, PGI2, and PGD2 whereas the lag phase was dose-dependently prolonged by adenosine.

It is concluded that platelet aggregation may be induced in some patients by standard heparin and by certain LMWH fractions or semi-synthetic analogues, independently of their molecular weight and anticoagulant activity.

Key words

Heparin-induced thrombocytopenia - Low molecular weight heparin - Semi-synthetic heparin analogues - Arachidonic acid pathway

PDF (709 kb)

References

References
1 Gollub S, Ulin AN. Heparin-induced thrombocytopenia in man. J Lab Clin Med 1962; 59: 430-435
2 Natelson EA, Lynch EC, Alfrey CP, Gross JB. Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy. Ann Intern Med 1969; 71: 1121-1125
3 Fratantoni JC, Pollet R, Gralwick HR. Heparin-induced thrombocytopenia: confirmation of diagnosis by in vitro methods. Blood 1975; 45: 395-401
4 Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med 1976; 295: 237-241
5 Bell WR, Tomasulo PA, Alving BM, Duffy TP. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann Intern Med 1976; 85: 155-160
6 Rhodes GR, Dixon RH, Silver D. Heparin-induced thrombocytopenia: eight cases with thrombotic hemorrhagic complications. Ann Surg 1977; 186: 752-758
7 Green D, Harris K, Reynolds N, Roberts M, Patterson R. Heparin immune thrombocytopenia: evidence for a heparin-platelet complex as the antigenic determinant. J Lab Clin Med 1978; 91: 167-175
8 Nelson JC, Lerner RG, Goldstein R, Cagin NA. Heparin-induced thrombocytopenia. Arch Intern Med 1978; 138: 548-552
9 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535-540
10 Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958; 76: 219-227
11 Baird RA, Convery FR. Arterial thromboembolism in patients receiving systemic heparin therapy. A complication associated with heparin-induced thrombocytopenia. J Bone Jt Surg (Am Vol) 1977; 59A: 1061-1064
12 Fiessinger JN, Aiach M, Roncato C, Gaux JC. Critical ischemia during heparin-induced thrombocytopenia. Treatment with intra-arterial streptokinase. Thromb Res 1984; 33: 235-238
13 Towne JB, Bernhard VM, Hussey C, Garancis JC. White-clot syndrome: peripheral vascular complications of heparin therapy. Arch Surg 1979; 114: 372-377
14 Roussi J, Houbouyan L, Rosenthal D, Toulemonde F, Goguel A. Succes du traitement par une héparine de bas poids moleculaire dans un cas d’embolie pulmonaire compliquant une thrombopenie induite par l’heparine. Nouv Rev Fr Hematol 1983; 25: 273-274
15 Klein HC, Bell WR. Disseminated intravascular coagulation during heparin therapy. Ann Intern Med 1974; 80: 477-481
16 Chong BH, Pitney WR, Castaldi PA. Heparin induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 1982; 2: 1246-1249
17 Carreras LO. Thrombosis and thrombocytopenia induced by heparin. In Clinical usage of heparin Present and future trends. Verstraete M, Machin SJ. (eds). Scand J Haematol 1980. 25 (suppl36) 64-80
18 Ehrlich J, Stivala SS. Chemistry and pharmacology of heparin. J Pharm Sci 1973; 62: 527-544
19 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
20 Roussi JH, Houbouyan LL, Goguel AF. Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet 1984; 1: 1183
21 Horellou MH, Conard J, Lescrubier C, Samama M, Roque d’Orbcastel O, de Fenoyl O, Di Maria G, Bemadou A. Persistent heparin-induced thrombocytopenia despite therapy with low-molecular weight heparin. Thromb Haemostas 1984; 51: 134
22 Gruel Y, Leroy J, Guerois C, Delahousse B, Briand T, Cibois D, Troulard D. Thrombopenie et thrombose sous héparine. Nécessité des tests d’agrégation avant le traitement par l’héparine de bas poids moléculaire. Presse Méd 1985; 14: 166
23 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res 1982; 26: 389-400
24 Tangen O, Berman HJ. Gel filtration of blood platelets: a methodological report. In Platelet function and thrombosis A review of methods. Mannucci PM, Gorini S. (eds). Plenum Press; New York - London, Advances in Experimental Medicine and Biology: 1972. 34 235-243
25 Thunberg L, Bäckström G, Grundberg H, Riesenfeld J, Lindahl U. The molecular size of the antithrombin binding sequence in heparin. FEBS Lett 1980; 117: 203-206
26 Gresele P, Deckmyn H, Huybrechts E, Vermylen J. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibitors by increasing the formation of prostaglandin D2. Biochem Pharmacol 1984; 33: 2083-2088
27 Bounameaux H, Marbet GA, Lammle B, Eichlisberger R, Duckert F. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time and plasma heparin concentration, and analysis of the behaviour of antithrombin III. Amer J Clin Pathol 1980; 74: 68-73
28 Huisse MG, Huet Y, Zygelman M, Guillin MC. Thrombopénie induite par l’héparine standard Tentative thérapeutique à l’aide d’une héparine de bas poids moléculaire. Presse Med 1983; 12: 643
29 Huisse MG, Guillin MC, Bezeaud A, Toulemonde F, Kitzis M, Andreassian B. Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractions. Thromb Res 1982; 27: 485-490